Overview

Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus

Status:
Completed

Trial end date:
2008-09-18

Target enrollment:

Participant gender:

Summary

The primary objective of the study was to assess the long-term safety of 30- and 60-mg daily doses of ospemifene in the treatment of Vulvar and Vaginal Atrophy (VVA) in postmenopausal women with an intact uterus.

Phase:

Phase 3

Details

Lead Sponsor:

Shionogi

Collaborator:

QuatRx Pharmaceuticals

Treatments:

Tamoxifen